A multicenter phase II study of Tac + mini MTX as GVHD prophylaxis in patients undergoing cord blood transplantatio
Not Applicable
- Conditions
- AML,ALL,MDS,M
- Registration Number
- JPRN-UMIN000031269
- Lead Sponsor
- orth Japan Hematology Study Group (NJHSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 33
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients who are positive for HIV antibody. 2. Patients with active other malignancies. 3. Patients with active infectious disease. 4. Women who are pregnant, of childbearing potential, or lactating. 5. Patients who has a prior history of allogeneic transplantation. 6.Patients who experienced serious hypersensitivity or anaphylaxis to MTX and who have large amount of pleural effusion or ascites. 7.Patients who are not eligible for this study at the discretion of the investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The incidence of grade III-IV acute GVHD at 100 days
- Secondary Outcome Measures
Name Time Method